DARK SECRETS: 4 | Vintage Vibes

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback.  It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Benzinga · Nov 24, 2025

Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results, pushing the share price through the roof.

Euronews · Nov 24, 2025

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Report dashes hopes for new use for blockbuster weight-loss drug

The Guardian - UK · Nov 24, 2025

Price of Wegovy and Ozempic weight loss drugs slashed with certain customers saving $150 per month

A recent poll found that about half of the people who take the treatments say it was hard to afford them

The Independent UK · Nov 17, 2025

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Benzinga · Nov 14, 2025

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga · Nov 11, 2025

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK · Nov 8, 2025

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy

For the previous edition of Deal Dispatch, click here.

Benzinga · Nov 7, 2025

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga · Nov 6, 2025

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK · Nov 6, 2025